Hubbry Logo
search button
Sign in
Melevodopa
Melevodopa
Comunity Hub
arrow-down
History
arrow-down
starMore
arrow-down
bob

Bob

Have a question related to this hub?

bob

Alice

Got something to say related to this hub?
Share it here.

#general is a chat channel to discuss anything related to the hub.
Hubbry Logo
search button
Sign in
Melevodopa
Community hub for the Wikipedia article
logoWikipedian hub
Welcome to the community hub built on top of the Melevodopa Wikipedia article. Here, you can discuss, collect, and organize anything related to Melevodopa. The purpose of the hub is to connect people, fos...
Add your contribution
Melevodopa

Melevodopa
Clinical data
Trade namesLevomet
Other namesLevodopa methyl ester; L-DOPA methyl ester; LDME; CHF-1301
ATC code
Identifiers
  • methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13NO4
Molar mass211.217 g·mol−1
3D model (JSmol)
  • O=C(OC)[C@@H](N)Cc1cc(O)c(O)cc1
  • InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1 checkY
  • Key:XBBDACCLCFWBSI-ZETCQYMHSA-N checkY
  (verify)

Melevodopa, also known as levodopa methyl ester (LDME) and sold under the brand name Levomet, is a dopaminergic agent. It is the methyl ester of levodopa.[1] It is used in oral tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa.[2][3] In combination with carbidopa, as melevodopa/carbidopa (brand name Sirio), it is approved for use in the treatment of Parkinson's disease.[4][5]

See also

[edit]

References

[edit]
  1. ^ Buckingham J, Baggaley K, Roberts A, Szabo L (2010). Dictionary of Alkaloids with CD-ROM. CRC Press. p. 103. ISBN 978-1-4200-7770-4. Retrieved 28 September 2024.
  2. ^ Hickey P, Stacy M (2011). "Available and emerging treatments for Parkinson's disease: a review". Drug Design, Development and Therapy. 5: 241–254. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
  3. ^ Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clin Neuropharmacol. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
  4. ^ "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
  5. ^ "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.